<- Go Home

Evolus, Inc.

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Market Cap

$442.5M

Volume

1.3M

Cash and Equivalents

$49.8M

EBITDA

-$23.2M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$199.3M

Profit Margin

66.06%

52 Week High

$10.62

52 Week Low

$3.86

Dividend

N/A

Price / Book Value

-15.37

Price / Earnings

-10.03

Price / Tangible Book Value

-4.57

Enterprise Value

$557.7M

Enterprise Value / EBITDA

-27.23

Operating Income

-$31.4M

Return on Equity

245.43%

Return on Assets

-9.06

Cash and Short Term Investments

$49.8M

Debt

$164.9M

Equity

-$28.8M

Revenue

$301.8M

Unlevered FCF

-$12.5M

Sector

Pharmaceuticals

Category

N/A

Company Stock Pitches